Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products
- PMID: 18977445
- DOI: 10.1016/j.semcancer.2008.10.008
Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products
Abstract
Upon primary infection, EBV establishes a latent infection in B cells, characterized by maintenance of the viral genome in the absence of viral replication. The Epstein-Barr Nuclear Antigen 1 (EBNA1) plays a crucial role in maintenance of the viral DNA episome and is consistently expressed in all EBV-associated malignancies. Compared to other EBV latent gene products, EBNA1 is poorly recognized by CD8(+) T lymphocytes. Recent studies are discussed that shed new light on the mechanisms that underlie this unusual lack of CD8(+) T cell activation. Whereas the latent phase is characterized by the expression of a limited subset of viral gene products, the full repertoire of over 80 EBV lytic gene products is expressed during the replicative phase. Despite this abundance of potential T cell antigens, which indeed give rise to a strong response of CD4(+) and CD8(+) T lymphocytes, the virus can replicate successfully. Evidence is accumulating that this paradoxical situation is the result of actions of multiple viral gene products, inhibiting discrete stages of the MHC class I and class II antigen presentation pathways. Immediately after initiation of the lytic cycle, BNLF2a prevents peptide-loading of MHC class I molecules through inhibition of the Transporter associated with Antigen Processing, TAP. This will reduce presentation of viral antigens by the large ER-resident pool of MHC class I molecules. Synthesis of new MHC class I molecules is blocked by BGLF5. Viral-IL10 causes a reduction in mRNA levels of TAP1 and bli/LMP2, a subunit of the immunoproteasome. MHC class I molecules present at the cell surface are downregulated by BILF1. Also the antigen presenting capacity of MHC class II molecules is severely compromised by multiple EBV lytic gene products, including gp42/gH/gL, BGLF5, and vIL-10. In this review, we discuss how concerted actions of these EBV lytic proteins result in highly effective interference with CD8(+) and CD4(+) T cell surveillance, thereby providing the virus with a window for undisturbed generation of viral progeny.
Similar articles
-
Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.PLoS Pathog. 2014 Aug 21;10(8):e1004322. doi: 10.1371/journal.ppat.1004322. eCollection 2014 Aug. PLoS Pathog. 2014. PMID: 25144360 Free PMC article.
-
Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6467-E6475. doi: 10.1073/pnas.1605884113. Epub 2016 Oct 3. Proc Natl Acad Sci U S A. 2016. PMID: 27698133 Free PMC article.
-
Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.PLoS Pathog. 2009 Jun;5(6):e1000490. doi: 10.1371/journal.ppat.1000490. Epub 2009 Jun 26. PLoS Pathog. 2009. PMID: 19557156 Free PMC article.
-
Immune Evasion by Epstein-Barr Virus.Curr Top Microbiol Immunol. 2015;391:355-81. doi: 10.1007/978-3-319-22834-1_12. Curr Top Microbiol Immunol. 2015. PMID: 26428381 Review.
-
Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.J Pathol. 2015 Jan;235(2):334-41. doi: 10.1002/path.4431. J Pathol. 2015. PMID: 25186125 Review.
Cited by
-
The viral etiology of EBV-associated gastric cancers contributes to their unique pathology, clinical outcomes, treatment responses and immune landscape.Front Immunol. 2024 Mar 26;15:1358511. doi: 10.3389/fimmu.2024.1358511. eCollection 2024. Front Immunol. 2024. PMID: 38596668 Free PMC article. Review.
-
Epstein-Barr virus: the mastermind of immune chaos.Front Immunol. 2024 Feb 7;15:1297994. doi: 10.3389/fimmu.2024.1297994. eCollection 2024. Front Immunol. 2024. PMID: 38384471 Free PMC article. Review.
-
Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation.Front Immunol. 2024 Jan 11;14:1290059. doi: 10.3389/fimmu.2023.1290059. eCollection 2023. Front Immunol. 2024. PMID: 38274824 Free PMC article. Review.
-
Are the integrin binding motifs within SARS CoV-2 spike protein and MHC class II alleles playing the key role in COVID-19?Front Immunol. 2023 Jul 10;14:1177691. doi: 10.3389/fimmu.2023.1177691. eCollection 2023. Front Immunol. 2023. PMID: 37492575 Free PMC article.
-
The innate and T-cell mediated immune response during acute and chronic gammaherpesvirus infection.Front Cell Infect Microbiol. 2023 Mar 31;13:1146381. doi: 10.3389/fcimb.2023.1146381. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37065193 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous